Barclays upgraded Smith & Nephew to Equal Weight from Underweight with an unchanged price target of 1,150 GBp. 2023 has been a year of two halves for medical technology, which saw share prices decouple from earnings in a similar way to 2020, the analyst tells investors in a research note. The firm expects a return to fundamentals in 2024 and sees a balanced risk/reward for Smith & Nephew shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SNN:
- Smith & Nephew initiated with a Buy at Goldman Sachs
- Smith & Nephew price target lowered to 1,500 GBp from 1,600 GBp at RBC Capital
- Smith & Nephew price target lowered to 1,150 GBp from 1,200 GBp at Barclays
- Smith & Nephew upgraded to Overweight from Neutral at JPMorgan
- Smith & Nephew upgraded to Buy from Hold at HSBC